Characterization of the Structural Features and Interactions of Sclerostin: MOLECULAR INSIGHT INTO A KEY REGULATOR OF Wnt-MEDIATED BONE FORMATION
about
Members of the DAN family are BMP antagonists that form highly stable noncovalent dimersModular mechanism of Wnt signaling inhibition by Wnt inhibitory factor 1Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathwaysThe DAN family: modulators of TGF-β signaling and beyondHigh Resolution NMR-based Model for the Structure of a scFv-IL-1 Complex: POTENTIAL FOR NMR AS A KEY TOOL IN THERAPEUTIC ANTIBODY DESIGN AND DEVELOPMENTMycobacterium tuberculosis RNA Polymerase-binding Protein A (RbpA) and Its Interactions with Sigma FactorsStructure of Protein Related to Dan and Cerberus: Insights into the Mechanism of Bone Morphogenetic Protein AntagonismA randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral densityWNT signaling in bone homeostasis and disease: from human mutations to treatmentsRegulation of Wnt/β-catenin signaling within and from osteocytesMutational analysis of sclerostin shows importance of the flexible loop and the cystine-knot for Wnt-signaling inhibitionStructure of Gremlin-1 and analysis of its interaction with BMP-2Structure of neuroblastoma suppressor of tumorigenicity 1 (NBL1): insights for the functional variability across bone morphogenetic protein (BMP) antagonists.Conformational heterogeneity in antibody-protein antigen recognition: implications for high affinity protein complex formationDevelopments in sclerostin biology: regulation of gene expression, mechanisms of action, and physiological functions.The Impact of Glucagon-Like Peptide-1 on Bone Metabolism and Its Possible Mechanisms.Bone mineral density and serum biochemical predictors of bone loss in patients with CKD on dialysis.Sclerostin: current knowledge and future perspectives.Serum sclerostin in high-activity adult patients with juvenile idiopathic arthritis.Romosozumab for the treatment of osteoporosis.Anti-Sclerostin antibody inhibits internalization of Sclerostin and Sclerostin-mediated antagonism of Wnt/LRP6 signaling.Sclerostin and Dickkopf-1 in renal osteodystrophy.An Akt-dependent increase in canonical Wnt signaling and a decrease in sclerostin protein levels are involved in strontium ranelate-induced osteogenic effects in human osteoblasts.Association of circulating sclerostin with vascular calcification in Afro-Caribbean men.Determination of serum and plasma sclerostin concentrations by enzyme-linked immunoassays.Crystallization and preliminary X-ray crystallographic analysis of the sclerostin-neutralizing Fab AbD09097.Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis.A Comprehensive Overview of Skeletal Phenotypes Associated with Alterations in Wnt/β-catenin Signaling in Humans and Mice.High Parathyroid Hormone Level and Osteoporosis Predict Progression of Coronary Artery Calcification in Patients on Dialysis.Sclerostin levels and bone turnover markers in adolescents with anorexia nervosa and healthy adolescent girls.Heparanase Overexpression Reduces Hepcidin Expression, Affects Iron Homeostasis and Alters the Response to Inflammation.Sclerostin inhibits osteoblast differentiation without affecting BMP2/SMAD1/5 or Wnt3a/β-catenin signaling but through activation of platelet-derived growth factor receptor signaling in vitroSclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calciumValidation of commercially available ELISAs for the detection of circulating sclerostin in hemodialysis patientsThe sclerostin-neutralizing antibody AbD09097 recognizes an epitope adjacent to sclerostin's binding site for the Wnt co-receptor LRP6TGF-β antagonists: same knot, but different hold.Monomeric gremlin is a novel vascular endothelial growth factor receptor-2 antagonist.Predicting intrinsic disorder in proteins: an overview.Relative influence of heritability, environment and genetics on serum sclerostinRole of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases.
P2860
Q24300782-81EE99EC-EB8A-4447-9CB8-2D5256B7F20EQ24609669-6B997947-D377-4802-AAE7-08C1C17FE361Q24621990-875C3305-63AB-4AA8-8E00-578590104B11Q27025762-E94DB2EA-8197-46BB-868B-40DE86B43D3CQ27657542-FFA8C553-F19C-4B65-933B-43DF107CAFC9Q27677177-2DD91402-687C-42E3-95F0-413F63C511CFQ27679073-BD1DF087-C969-4CDA-AD41-7F5837DD962FQ28247445-7044B997-6784-4664-A541-1E1AE17E0F6CQ28285090-B187FE33-4EBB-47D3-A004-31FF7F7E6550Q28286814-0BF90C73-1273-4DB0-830A-4C10627796CDQ28535490-8F321803-0F76-44BC-982B-5A4FAD2574DCQ30090218-CDFB983D-0E9D-4DB5-9D73-36F9E4F25E4EQ30090227-F420D8C8-CCE9-40E8-B2A6-69FE892293D3Q30357995-4522D96C-530E-4D6E-9EE0-40865F426336Q33564617-AA283FF7-D1F3-4697-AC03-9F487296D6C0Q33627749-88C72C3C-524A-41E0-9E70-658A37899543Q33835723-F61F8881-9B00-4B8A-A356-0D6057E73C9AQ33992612-4EE2284E-1A4D-45ED-806F-9B3837AB7999Q34537434-D500B834-ABEC-4CD0-BF70-510034CEB85EQ34680463-EADE10BE-4E83-4E3F-8694-E8DF5574CE74Q34701183-FFBB1304-6343-4284-B0BE-1F473309F3F0Q34751932-A04C7B11-A390-4C57-A974-68B57434F9CAQ35085009-9DA1B79C-22A1-4932-AE03-321D6AF5289CQ35091260-AA1182EB-E0DC-4802-A751-4B0B0B0699EEQ35101832-FDA2B328-26B8-4FE3-B6CF-F3838A0D9837Q35596559-FBD5CC3C-1F42-480D-91A1-FC634452B161Q35694436-05587C55-7E31-4AE0-B7D5-5A11E46EB8ECQ35755034-5811994E-B021-436C-A50D-38B0FDA58076Q36104814-72E263D2-BE60-46E8-88F7-06B0ADC351ADQ36143916-F980C0C2-F62B-44E0-8CE0-D0CDC8ADC4B2Q36155327-C9B5F7B2-6FAE-486D-95DA-FBA637C7A203Q36256294-800AE43E-53A2-4C98-9B8B-966FF2DAB071Q36762750-112C2D5F-D0AF-4B9C-9BF6-5DFC78BB4F04Q36793394-663C59F0-C984-4214-8C76-4AA85B38069CQ37224687-AC6DEE61-E77E-4A52-93B2-1EA064AE4E4DQ37257108-7E04AB25-3EF7-441D-A906-F4B9DCB34E35Q37376551-D2EC4784-7BC7-4AE8-B011-C901C3A2D666Q37549950-7FB258B7-EF74-4E62-9F97-CB21E28C76CBQ37627846-6D6CF5A6-BC86-443D-9CCA-AE65F0657968Q37640833-9664DFD6-D715-467E-8FCA-27B9A1AABB3F
P2860
Characterization of the Structural Features and Interactions of Sclerostin: MOLECULAR INSIGHT INTO A KEY REGULATOR OF Wnt-MEDIATED BONE FORMATION
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Characterization of the Struct ...... OF Wnt-MEDIATED BONE FORMATION
@ast
Characterization of the Struct ...... OF Wnt-MEDIATED BONE FORMATION
@en
Characterization of the Struct ...... OF Wnt-MEDIATED BONE FORMATION
@nl
type
label
Characterization of the Struct ...... OF Wnt-MEDIATED BONE FORMATION
@ast
Characterization of the Struct ...... OF Wnt-MEDIATED BONE FORMATION
@en
Characterization of the Struct ...... OF Wnt-MEDIATED BONE FORMATION
@nl
prefLabel
Characterization of the Struct ...... OF Wnt-MEDIATED BONE FORMATION
@ast
Characterization of the Struct ...... OF Wnt-MEDIATED BONE FORMATION
@en
Characterization of the Struct ...... OF Wnt-MEDIATED BONE FORMATION
@nl
P2093
P2860
P3181
P356
P1476
Characterization of the Struct ...... OF Wnt-MEDIATED BONE FORMATION
@en
P2093
Adrian Moore
Alistair J Henry
Andrew Ventom
Barbara Mulloy
Chris Paszty
Frederick W Muskett
Jianhua Gong
Kevin Greenslade
Mariusz Muzylak
P2860
P304
P3181
P356
10.1074/JBC.M807994200
P407
P577
2009-04-17T00:00:00Z